These top ASX 200 stocks could rise 25% to 60%

These shares could be cheap at current levels according to analysts.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Cochlear is poised for long-term growth driven by increasing global demand for hearing implants, supported by ageing populations and expanding healthcare access, with UBS setting a buy rating and a 25% upside price target of $350.
  • ResMed is capitalising on the vast undiagnosed sleep apnoea market, with innovations and a robust cloud ecosystem creating strong recurring revenue potential, as noted by Macquarie’s 25% upside prediction and $49.20 price target.
  • Xero, a leader in cloud accounting, is positioned for substantial growth with a vast untapped market of small businesses, offering a tremendous 60% upside potential according to Ord Minnett, driven by its expanding global footprint and digital adoption trends.

If you are looking for quality ASX 200 stocks to buy for big potential returns, then read on!

Listed below are three shares that analysts believe can rise very strongly from where they trade today.

After which, they have the potential to compound and build wealth for investors long into the future. Here's why they could be top picks right now:

Two happy and excited friends in euphoria holding a smartphone, after winning in a bet.

Image source: Getty Images

Cochlear Ltd (ASX: COH)

The first ASX 200 stock that could be a top buy is hearing implant leader Cochlear. It appears well position for growth over the long term thanks to rising demand for its devices on the back of ageing populations across the globe and broader access to hearing healthcare.

And with a robust balance sheet and a track record of delivering both earnings and dividend growth, Cochlear could be a blue chip to buy and hold onto for the next decade.

UBS currently rates Cochlear as a buy with a $350.00 price target. This implies potential upside of 25% for investors over the next 12 months.

ResMed Inc. (ASX: RMD)

Another ASX 200 stock to buy and hold could be ResMed. With more than one billion people worldwide estimated to suffer from sleep apnoea, and the vast majority undiagnosed, ResMed has a significant growth runway over the next decade and beyond. The company continues to innovate across masks, devices and software while benefiting from rising awareness and diagnosis rates. Its cloud-connected ecosystem creates sticky customer relationships and high recurring revenue. For investors seeking a defensive growth story backed by secular demand, ResMed could be a top pick.

Macquarie has an outperform rating and $49.20 price target on its shares. This suggests that upside of 25% is possible for investors from current levels.

Xero Ltd (ASX: XRO)

A third ASX 200 stock to consider buying and holding is Xero. It is one of the world's leading cloud accounting platforms and still has a huge global market to chase. With more than 4.5 million subscribers and NZ$2.7 billion in annualised monthly recurring revenue, the company remains in the early stages of penetrating a total addressable market estimated at around 100 million small businesses. As digital adoption accelerates in the UK, North America and Asia, Xero's subscription model and high customer lifetime value create a powerful long-term growth engine.

Ord Minnett is bullish on Xero's outlook. It recently put a buy rating and $200.00 price target on its shares. This implies potential upside of 60% for investors between now and this time next year.

Motley Fool contributor James Mickleboro has positions in Cochlear, ResMed, and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear, Macquarie Group, ResMed, and Xero. The Motley Fool Australia has positions in and has recommended Macquarie Group, ResMed, and Xero. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

A young woman looks happily at her phone in one hand with a selection of retail shopping bags in her other hand.
Blue Chip Shares

If I invest $10,000 in Wesfarmers shares, how much passive income will I get in FY27?

The conglomerate has a long history of paying dividends to shareholders every six months.

Read more »

Woman with her kitten on a laptop in her home office.
Blue Chip Shares

Buy, hold, sell: Coles, Woodside & Telstra shares

Find out what the experts tip for these three well-known ASX shares.

Read more »

Person holding a blue chip.
Blue Chip Shares

2 ASX blue-chip shares experts rate as compelling

These businesses have a compelling outlook according to fund managers…

Read more »

Increasing stack of blue chips with a rising red arrow.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These businesses can deliver investors pleasing passive income.

Read more »

Stressed shopper holding shopping bags.
Retail Shares

Should I invest $6,000 in Wesfarmers shares in August?

Here's what brokers tip for the retail conglomerate’s shares now.

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

Down 31%: Is it time to buy this popular ASX 200 blue chip?

Is it time to be bullish or bearish on this fallen giant? Here's what analysts are saying.

Read more »

A man surrounded by huge piles of paper looks through a magnifying glass at his computer screen.
Blue Chip Shares

Buy, hold, sell: Telstra, BHP, CSL shares

At the time of writing, brokers tip some element of upside from each of these ASX shares. Find out more…

Read more »

A man wearing a colourful shirt holds an old fashioned phone to his ear with a look of curiosity on his face as though he is pondering the answer to a question.
Dividend Investing

If you invested $10,000 in Telstra shares 10 years ago, here's what you'd have today

The capital went backwards. The income did the work.

Read more »